Country Club Bank Has $1.37 Million Stake in Quest Diagnostics Incorporated $DGX

Country Club Bank decreased its position in shares of Quest Diagnostics Incorporated (NYSE:DGX) by 5.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,692 shares of the medical research company’s stock after selling 445 shares during the quarter. Country Club Bank’s holdings in Quest Diagnostics were worth $1,368,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Pinnacle Bancorp Inc. boosted its holdings in shares of Quest Diagnostics by 126.9% during the 2nd quarter. Pinnacle Bancorp Inc. now owns 152 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 85 shares in the last quarter. Bruce G. Allen Investments LLC lifted its holdings in Quest Diagnostics by 57.8% during the 1st quarter. Bruce G. Allen Investments LLC now owns 183 shares of the medical research company’s stock worth $31,000 after buying an additional 67 shares during the period. First Horizon Advisors Inc. lifted its holdings in Quest Diagnostics by 76.6% during the 1st quarter. First Horizon Advisors Inc. now owns 189 shares of the medical research company’s stock worth $32,000 after buying an additional 82 shares during the period. Golden State Wealth Management LLC lifted its holdings in Quest Diagnostics by 157.3% during the 1st quarter. Golden State Wealth Management LLC now owns 193 shares of the medical research company’s stock worth $33,000 after buying an additional 118 shares during the period. Finally, NBC Securities Inc. acquired a new position in Quest Diagnostics during the 1st quarter worth about $35,000. Institutional investors and hedge funds own 88.06% of the company’s stock.

Quest Diagnostics Stock Performance

Shares of Quest Diagnostics stock opened at $181.95 on Wednesday. Quest Diagnostics Incorporated has a one year low of $146.53 and a one year high of $191.49. The firm has a market capitalization of $20.35 billion, a price-to-earnings ratio of 21.79, a PEG ratio of 2.37 and a beta of 0.56. The business has a 50-day simple moving average of $180.42 and a 200 day simple moving average of $175.22. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.09 and a quick ratio of 0.99.

Quest Diagnostics (NYSE:DGX) last issued its earnings results on Tuesday, July 22nd. The medical research company reported $2.62 EPS for the quarter, beating analysts’ consensus estimates of $2.57 by $0.05. Quest Diagnostics had a return on equity of 15.24% and a net margin of 9.01%.The business had revenue of $2.76 billion during the quarter, compared to analyst estimates of $2.73 billion. During the same period in the previous year, the company posted $2.35 EPS. The firm’s revenue was up 15.2% compared to the same quarter last year. Quest Diagnostics has set its FY 2025 guidance at 9.630-9.830 EPS. On average, research analysts anticipate that Quest Diagnostics Incorporated will post 9.7 earnings per share for the current fiscal year.

Quest Diagnostics Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, October 20th. Investors of record on Friday, October 3rd will be given a $0.80 dividend. This represents a $3.20 dividend on an annualized basis and a yield of 1.8%. The ex-dividend date of this dividend is Friday, October 3rd. Quest Diagnostics’s payout ratio is presently 38.32%.

Analysts Set New Price Targets

Several research analysts have commented on the company. Barclays lifted their target price on Quest Diagnostics from $185.00 to $190.00 and gave the stock an “equal weight” rating in a report on Thursday, October 2nd. William Blair reissued an “outperform” rating on shares of Quest Diagnostics in a research report on Wednesday, July 23rd. Weiss Ratings reissued a “buy (b)” rating on shares of Quest Diagnostics in a research report on Saturday, September 27th. Deutsche Bank Aktiengesellschaft lifted their price objective on Quest Diagnostics from $160.00 to $178.00 and gave the stock a “hold” rating in a research report on Wednesday, July 23rd. Finally, Robert W. Baird reissued a “neutral” rating and issued a $194.00 price objective on shares of Quest Diagnostics in a research report on Monday, August 25th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and ten have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $186.31.

Insider Activity at Quest Diagnostics

In other Quest Diagnostics news, SVP Michael E. Prevoznik sold 227 shares of the business’s stock in a transaction that occurred on Friday, September 26th. The stock was sold at an average price of $188.13, for a total transaction of $42,705.51. Following the completion of the sale, the senior vice president directly owned 38,117 shares of the company’s stock, valued at approximately $7,170,951.21. The trade was a 0.59% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Karthik Kuppusamy sold 2,210 shares of the business’s stock in a transaction that occurred on Thursday, July 31st. The stock was sold at an average price of $170.00, for a total value of $375,700.00. Following the sale, the senior vice president directly owned 8,450 shares of the company’s stock, valued at $1,436,500. This represents a 20.73% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 53,186 shares of company stock valued at $9,647,471 in the last three months. Corporate insiders own 8.16% of the company’s stock.

About Quest Diagnostics

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.